NASDAQ:MDCX Medicus Pharma (MDCX) Stock Price, News & Analysis $2.70 +0.27 (+11.11%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medicus Pharma Stock (NASDAQ:MDCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medicus Pharma alerts:Sign Up Key Stats Today's Range$2.57▼$2.7850-Day Range$1.83▼$2.8052-Week Range$1.79▼$8.94Volume876,456 shsAverage Volume260,511 shsMarket Capitalization$48.11 millionP/E RatioN/ADividend YieldN/APrice Target$23.50Consensus RatingModerate Buy Company Overview Medicus Pharma, Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer. Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access. Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.AI Generated. May Contain Errors. Read More Medicus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreMDCX MarketRank™: Medicus Pharma scored higher than 45% of companies evaluated by MarketBeat, and ranked 617th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMedicus Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMedicus Pharma has a consensus price target of $23.50, representing about 770.4% upside from its current price of $2.70.Amount of Analyst CoverageMedicus Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Medicus Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Medicus Pharma are expected to decrease in the coming year, from ($1.14) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicus Pharma is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicus Pharma is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedicus Pharma has a P/B Ratio of 9.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medicus Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.71% of the float of Medicus Pharma has been sold short.Short Interest Ratio / Days to CoverMedicus Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medicus Pharma has recently increased by 23.15%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedicus Pharma does not currently pay a dividend.Dividend GrowthMedicus Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.71% of the float of Medicus Pharma has been sold short.Short Interest Ratio / Days to CoverMedicus Pharma has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medicus Pharma has recently increased by 23.15%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.41 News SentimentMedicus Pharma has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Medicus Pharma this week, compared to 3 articles on an average week.Search Interest37 people have searched for MDCX on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.MarketBeat Follows34 people have added Medicus Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 79% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medicus Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.20% of the stock of Medicus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Medicus Pharma's insider trading history. Receive MDCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDCX Stock News HeadlinesD. Boral Capital Reiterates Buy Rating for Medicus Pharma (NASDAQ:MDCX)October 24 at 3:45 AM | americanbankingnews.com4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)October 24 at 3:41 AM | theglobeandmail.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 24 at 2:00 AM | Porter & Company (Ad)Medicus Pharma announces first patient treated in UAE SKNJCT-004 Phase 2 studyOctober 22 at 7:45 PM | msn.comMedicus Pharma doses first patient in UAE Phase 2 skin cancer studyOctober 22 at 9:06 AM | proactiveinvestors.comMedicus Pharma Completes Share Sales to YA II PNOctober 17, 2025 | tipranks.comBrokerages Set Medicus Pharma Ltd (NASDAQ:MDCX) Price Target at $23.50October 17, 2025 | americanbankingnews.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalOctober 16, 2025 | americanbankingnews.comSee More Headlines MDCX Stock Analysis - Frequently Asked Questions How have MDCX shares performed this year? Medicus Pharma's stock was trading at $2.43 on January 1st, 2025. Since then, MDCX stock has increased by 11.1% and is now trading at $2.70. How were Medicus Pharma's earnings last quarter? Medicus Pharma Ltd (NASDAQ:MDCX) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.04. When did Medicus Pharma IPO? Medicus Pharma (MDCX) raised $4 million in an initial public offering on Thursday, November 14th 2024. The company issued 1,000,000 shares at $4.13 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital Markets was co-manager. Who are Medicus Pharma's major shareholders? Medicus Pharma's top institutional investors include Brave Asset Management Inc. (0.11%). View institutional ownership trends. How do I buy shares of Medicus Pharma? Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2025Today10/24/2025Next Earnings (Estimated)11/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDCX Previous SymbolNASDAQ:MDCX CIK1997296 Webwww.medicuspharma.com Phone732-300-3046FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Medicus Pharma$23.50 High Price Target$27.00 Low Price Target$20.00 Potential Upside/Downside+828.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.16 million Net MarginsN/A Pretax MarginN/A Return on Equity-549.30% Return on Assets-228.06% Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book8.72Miscellaneous Outstanding Shares17,820,000Free Float15,821,000Market Cap$45.08 million OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:MDCX) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.